Sirtex, SingHealth to explore nanoparticles in treating cancer

12/6/2012 | Genetic Engineering & Biotechnology News

Sirtex Medical and SingHealth have entered a deal to develop the use of carbon-cage nanoparticles in treating cancer. The technology is based on Technegas, which is used in nuclear medicine as an inhalable aerosol of carbon-cage nanoparticles for detecting blood clots in the lungs. The first research initiative under the partnership will explore the technology as a treatment for advanced ovarian cancer that has metastasized in the abdomen and pelvic region.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT